Research Article
Volume 8 Issue 6 - 2021
Association of the Use of Gastric Acid Suppressants and Risk of Inflammatory Bowel Disease Exacerbation in Adult Patients: A Systematic Review and Meta-Analysis
Raymundo Nikko1,2*, Yasay Eric2 and Lontok Marie Antoinette1
1Institute of Digestive and Liver Diseases, St. Luke’s Medical Center Global City, Manila, Philippines
2Department of Clinical Epidemiology, College of Medicine, University of the Philippines, Manila, Philippines
*Corresponding Author: Raymundo Nikko, Institute of Digestive and Liver Diseases, St. Luke’s Medical Center Global City and Department of Clinical Epidemiology, College of Medicine, University of the Philippines, Manila, Philippines.
Received: May 11, 2021; Published: June 11, 2021




Abstract

Background: Gastric acid suppressants such as proton pump inhibitors (PPI) and histamine 2 receptor antagonists (H2RAs) are common gastrointestinal medications used to manage symptoms of acid related diseases. Studies have shown that these medications are associated with increased risk of pneumonia, vitamin deficiency, osteoporosis and fractures. Few studies have described the potential risk of inflammatory bowel disease (IBD) exacerbation among patients on gastric acid suppressants but little is known on its association. This study aims to investigate the effect of the use of gastric acid suppressants (PPI and H2RA) in the risk of IBD (Crohn’s disease and ulcerative colitis) exacerbation.

Methods: A comprehensive, computerized literature search from the electronic database of MEDLINE, Google scholar, Cochrane Library, and OVID was performed with the following search terms: gastric acid suppressants, proton pump inhibitors, histamine-2-receptor antagonists, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, outcomes, and disease activity exacerbation. Two cohort studies were selected and validated using the GRADE and Newcastle-Ottawa criteria. Trial results were combined under a random effects model using pooled adjusted relative risks (RRs). The Cochrane Review Manager Software version 5.4 was used for all analyses.

Results: Two cohort studies comprising of 36,293 patients were analyzed by pooling reported adjusted RRs using the random effects model. Disease activity exacerbation was associated with the use of gastric acid suppressants with pooled adjusted RR 1.14 [95% CI, 1.08 - 1.20, I2 = 0%] with no heterogeneity. The effects of PPIs and H2RAs were also separately analyzed. The pooled adjusted RR of IBD activity exacerbation with the use of PPIs was 1.12 [95% CI, 1.05 - 1.19, I2 = 0%] for any IBD, while the pooled adjusted RR of disease activity exacerbation with the use of H2RAs was 1.21 [1.04 - 1.40, I2 = 42%] for any IBD, with moderate heterogeneity. The effect of acid suppression was more marked in patients with Crohn’s disease, RR 1.44 [0.89 - 2.33, I2 = 77%], but this was statistically insignificant with marked heterogeneity; than in ulcerative colitis RR 1.12 [1.05 - 1.20, I2 = 0%].

Conclusion: Use of gastric acid suppressants such as PPIs and H2Ras may be associated with increased risk of disease exacerbation in patients with IBD. This meta-analysis confirms the need for further prospective studies in examining this relationship.

 

Keywords: Proton Pump Inhibitor; Histamine 2 Receptor Antagonist; Inflammatory Bowel Disease

References

  1. Matsuoka K., et al. “Evidence-based clinical practice guidelines for inflammatory bowel disease”. Journal of Gastroenterology 53 (2018): 305-353.
  2. Ng SC., et al. “Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies”. Lancet 390 (2017): 2769-2778.
  3. Fiocchi C. “Inflammatory Bowel Disease: Etiology and Pathogenesis”. Gastroenterology 115 (1998): 182-205.
  4. Xavier RJ and Podolsky DK. “Unravelling the pathogenesis of inflammatory bowel disease”. Nature 448 (2007): 427-434.
  5. Fakhoury M., et al. “Inflammatory bowel disease: clinical aspects and treatments”. Journal of Inflammation Research 7 (2014): 113-120.
  6. Levine JS and Burakoff R. “Extraintestinal Manifestations of Inflammatory Bowel Disease”. Journal of Gastroenterology and Hepatology4 (2011): 235-241.
  7. Hanauer SB. “Inflammatory Bowel Disease: Epidemiology, Pathogenesis, and Therapeutic Opportunities”. Inflammatory Bowel Disease 12 (2006): S3-S9.
  8. Rubin DT., et al. “Impact of ulcerative colitis from patients’ and physicians’ perspectives: Results form the UC: NORMAL survey”. Inflammatory Bowel Disease 4 (2009): 581-588.
  9. Axelrad JE., et al. “Enteric Infections are Common in Patients with Flares of Inflammatory Bowel Disease”. The American Journal of Gastroenterology10 (2018): 1530-1539.
  10. Feagins LA., et al. “Case-control study of factors that trigger inflammatory bowel disease flares”. World Journal of Gastroenterology15 (2014): 4329-4334.
  11. Reinink AR. “Do Acid-Suppressing Medications in Inflammatory Bowel Disease Increase Risk for Flare?” Digestion 95 (2017): 186-187.
  12. Hálfdánasrson ÓÖ., et al. “Proton-pump inhibitors among adults: a nationwide drug utilization study”. Therapeutic Advances in Gastroenterology 11 (2018): 1-11.
  13. Bruno G., et al. “Proton pump inhibitors and dysbiosis: Current knowedge and aspects to be clarified”. World Journal of Gastroenterology22 (2019): 2706-2719.
  14. Schwartz NR., et al. “Proton Pump Inhibitors, H2 Blocker Use, and Risk of Inflammatory Bowel Disease in Children”. The Journal of Pediatric Pharmacology and Therapeutics6 (2019): 489-496.
  15. Juillerat P., et al. “Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease”. Alimentary Pharmacology and Therapeutics 36 (2012): 239-247.
  16. Shah R., et al. “Gastric Acid Suppression Is Associated with an Increased Risk of Adverse Outcomes in Inflammatory Bowel Disease”. Digestion 95 (2017): 188-193.
  17. Moninuola OO., et al. “Systematic Review and Meta-analysis: Association Between Acetaminophen and Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Risk of Crohn’s Disease and Ulcerative Colitis Exacerbation”. Alimentary Pharmacology and Therapeutics11 (2018): 1428-1439.
  18. Takagi T., et al. “The influence of long-term use of proton pump inhibitors on the gut microbiota: an age-sex-matched case control study”. Journal of Clinical Biochemistry and Nutrition1 (2018): 100-105.
  19. Smolinska S., et al. “Histamine Receptor 2 is Required to Suppress Innate Immune Responses to Bacterial Ligands in Patients with Inflammatory Bowel Disease”. Inflammatory Bowel Disease7 (): 1575-1586.
Citation: Raymundo Nikko., et al. “Association of the Use of Gastric Acid Suppressants and Risk of Inflammatory Bowel Disease Exacerbation in Adult Patients: A Systematic Review and Meta-Analysis”. EC Gastroenterology and Digestive System 8.7 (2021): 11-21.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


January Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before February 13, 2023.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.